The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.

Grace Hyun J KimJonathan G GoldinWendy HayesAndrea OhBenjamin SouleShuyan Du

Published in: Therapeutic advances in respiratory disease (2021)

This study demonstrated the utility of quantitative HRCT as an efficacy endpoint for IPF in a double-blind, placebo-controlled clinical trial setting.The reviews of this paper are available via the supplemental material section.

Keyphrases

phase ii
idiopathic pulmonary fibrosis
clinical trial
placebo controlled
open label
double blind
high resolution
phase iii
interstitial lung disease
study protocol
rheumatoid arthritis
phase ii study
systematic review
mass spectrometry
locally advanced